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Abstract
The cellular prion protein PrP(C) confers susceptibility to transmissible spongiform encephalopathies,
yet its normal function is unknown. Although PrP(C)-deficient mice develop and live normally,
expression of amino proximally truncated PrP(C) (DeltaPrP) or of its structural homolog Doppel (Dpl)
causes cerebellar degeneration that is prevented by coexpression of full-length PrP(C). We now report
that mice expressing DeltaPrP or Dpl suffer from widespread leukoencephalopathy.
Oligodendrocyte-specific expression of full-length PrP(C) under control of the myelin basic protein
(MBP) promoter repressed leukoencephalopathy and vastly extended survival but did not prevent
cerebellar granule cell (CGC) degeneration. Conversely, neuron-specific PrP(C) expression under
control of the neuron-specific enolase (NSE) promoter antagonized CGC degeneration but not
leukoencephalopathy. PrP(C) was found in purified myelin and in cultured oligodendrocytes of both
wild-type and MBP-PrP transgenic mice but not in NSE-PrP mice. These results identify white-matter
damage as an extraneuronal PrP-associated pathology and suggest a previously unrecognized role of
PrP(C) in myelin maintenance.
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Truncated Prion Protein and Doppel Are Myelinotoxic in the
Absence of Oligodendrocytic PrPC
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The cellular prionproteinPrPC confers susceptibility to transmissible spongiformencephalopathies, yet its normal function is unknown.
Although PrPC-deficient mice develop and live normally, expression of amino proximally truncated PrPC (PrP) or of its structural
homolog Doppel (Dpl) causes cerebellar degeneration that is prevented by coexpression of full-length PrPC. We now report that mice
expressing PrP or Dpl suffer from widespread leukoencephalopathy. Oligodendrocyte-specific expression of full-length PrPC under
control of the myelin basic protein (MBP) promoter repressed leukoencephalopathy and vastly extended survival but did not prevent
cerebellar granule cell (CGC) degeneration. Conversely, neuron-specific PrPC expression under control of the neuron-specific enolase
(NSE) promoter antagonized CGC degeneration but not leukoencephalopathy. PrPC was found in purified myelin and in cultured
oligodendrocytes of both wild-type andMBP-PrP transgenic mice but not in NSE-PrPmice. These results identify white-matter damage
as an extraneuronal PrP-associated pathology and suggest a previously unrecognized role of PrPC in myelin maintenance.
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Introduction
The infectious agent causing transmissible spongiform encepha-
lopathies (TSE) was termed prion (Prusiner, 1982). Its only
known constituent is PrPSc, a TSE-associated isoform of the cel-
lular prion protein PrPC. Ablation of the Prnp gene, which en-
codes PrPC, abrogates prion replication (Bu¨eler et al., 1993) and
scrapie pathogenesis (Brandner et al., 1996), but the physiologi-
cal function of PrPC has remained elusive (Aguzzi and Poly-
menidou, 2004). Prnpo/o mice show no obvious developmental
defects and enjoy a normal life expectancy (Bu¨eler et al., 1992).
Subtle changes in circadian rhythms (Tobler et al., 1996), alter-
ations of hippocampal function (Collinge et al., 1994; Colling et
al., 1997; Herms et al., 1999;Mallucci et al., 2002), and behavioral
abnormalities have been described. However, some of these phe-
notypes were not reproduced by others (Lledo et al., 1996), and
none were clarified in molecular terms. PrPC binds copper
(Brown et al., 1997; Kretzschmar et al., 2000) and may have an-
tiapoptotic properties (Kuwahara et al., 1999; Bounhar et al.,
2001; Chiarini et al., 2002; Zanata et al., 2002) but could also
sensitize neurons to apoptotic stimuli (Paitel et al., 2003). A pos-
sible dismutase activity of PrPC was not confirmed in vivo (Wag-
goner et al., 2000; Hutter et al., 2003). Several factors bind PrPC,
including the laminin receptor precursor protein (Rieger et al.,
1997), heparan sulfate (Caughey et al., 1994), neural cell adhesion
molecule (NCAM) (Schmitt-Ulms et al., 2001), and bcl-2 (Kur-
schner et al., 1995). However, none of these interactions were
shown to be functionally significant. Hence, no unified view of
PrPC function has emerged from the above observations.
Transgenic expression of amino proximally truncated PrPC
mutants causes early-onset ataxia associated with progressive
cerebellar granule cell (CGC) degeneration and death at 3–4
months of age, also referred to as Shmerling’s syndrome (Shmer-
ling et al., 1998). Only truncated versions of PrPC encompassing
half (amino acids 34–121) or all (amino acids 34–134) of the
highly conserved hydrophobic transmembrane domain 1 (TM1)
region (amino acids 113–134) (collectively termed PrP) induce
disease. A similar neurodegenerative phenotype affecting cere-
bellar Purkinje cells was observed in compound heterozygous
Prnpo/ZHII mice and in homozygous PrnpZHII/ZHII mice (Rossi et
al., 2001), whose targeted PrnpZHII allele (termed “ZHII” because
itwas the second targeting event ofPrnp executed inZurich) leads to
overexpression of the PrPC homolog Doppel (Dpl) (Weissmann
andAguzzi, 1999). This phenotype is only observed in Prnpo/o mice
that overexpress PrP or Dpl and is fully reverted by substoichio-
metric coexpressionof full-lengthPrPC, as either theoriginal endog-
enous Prnp locus or a transgene under transcriptional control of a
“half-genomic”miniversion of Prnp (Fischer et al., 1996). It follows
thatPrP and Dpl interfere with a physiological function of PrPC.
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Here we show that, in addition to CGC degeneration, mice
expressing PrP or Dpl in their brain suffer from widespread
cerebellar leukoencephalopathy. Oligodendrocyte-specific ex-
pression of PrPC repressed this pathology and restored long-term
survival but did not rescue CGC death. Conversely, neuron-
specific expression of PrPC delayed disease onset and antago-
nized, to some extent, CGC degeneration but did not prevent
white-matter degeneration. Therefore, white-matter disease and
CGC degeneration are independent of each other. Surprisingly,
white-matter disease appears to represent a major survival-
limiting pathology induced by a toxic PrP mutant.
Materials andMethods
Generation of myelin basic protein-PrP and neuron-specific enolase-PrP
transgenic mice. Mice hemizygously transgenic for the F35(PrP32–
134)/ allele (Shmerling et al., 1998) and hemizygous for the ablated
endogenous Prnp locus (Prnp/ZHI) (Bu¨eler et al., 1992) are referred to
asPrPomice.Myelin basic protein (MBP)-PrP tg/;Prnpo/omice (Prinz
et al., 2004) were crossed to PrPo or to compound PrnpZHI/ZHII-Lox1
mice (Rossi et al., 2001). The wild-type and neo-targeted Prnp loci were
detected by PCR analysis of tail DNA as described previously (Bu¨eler et
al., 1992), the F35(PrP32–134) transgene was detected as described previ-
ously (Shmerling et al., 1998), and the ZHII-lox1 locus was also detected as
described previously (Rossi et al., 2001). To detect the MBP-PrP transgene,
the following primers were used: 5-ggc aac gtg ctg gtt att gtg c-3 and 5-tcc
cca gca tgt agc cac caa gg-3 (annealing at 58°C). For the generation of
neuron-specific enolase (NSE)-PrP/;F35(PrP32–134)/ mice, NSE-
PrP/;Prnpo/o mice were crossed with F35(PrP32–134)/;Prnp/0
animals. Primers usedwere as follows: Prnpint2, 5-ATACTGGGCACT
GAT ACC TTG TTC CTCA T; P10rev, 5-GCT GGG CTT GTT CCA
CTGATTATGGGTAC. These primers amplify selectively the wild-type
Prnp allele but not the NSE-PrP transgene and were used to identify
animals negative for wild-type Prnp. Standard PCR for Prnp (Bu¨eler et
al., 1992) detected both the NSE-PrP and the wild-type Prnp allele and
was used to confirm the inheritance of the NSE-PrP in animals lacking
wild-type Prnp. Onset of disease was declared when animals exhibited
unambiguous tremor or unsteady gait that was blindly recognizable from
healthy littermates in the same cage by two different observers. Animals
were considered to be at a terminal disease stage when they developed
hindlimb paralysis and were unable to reposition for 10 s after having
been turned back-down.
Histopathology. Organs were fixed in 4% paraformaldehyde (PFA) in
PBS, pH 7.5, paraffin embedded, and cut into 2 m sections. Brain
sections were stained with hematoxylin-eosin, Luxol-Nissl (myelin and
neurons), and commercial antibodies to GFAP (Dako, Carpinteria, CA),
microtubule-associated protein-2 (MAP-2) (Chemicon, Temecula, CA),
CNPase (Roche, Basel, Switzerland), or phosphorylated neurofilament
protein (Sigma, St. Louis, MO). For major histocompatibility complex
class II (MHC-II) andCD11b stains, tissueswere snap frozen inOCT, cut
on a vibratome, and stainedwith antibodies to CD11b (PharMingen, San
Diego, CA) or MHC-II (Serotec, Oxford, UK). Antibody stainings were
visualized using the peroxidase–anti-peroxidase method or a fluorescent
secondary antibody. Apoptosis was assessed using the in situ cell death kit
(Roche) according to the instructions of the manufacturer.
Semithin sections and electron microscopy. Mice were perfused with
ice-cold 4% PFA/3% glutaraldehyde. Brains and spinal cord were re-
moved, immersed in the same solutions, and kept at 4°Cuntil processing.
Tissues were embedded in Epon, and semithin sections were stainedwith
toluidine blue or used for electron microscopy.
Myelin preparation. Myelin was purified from mouse brains as de-
scribed previously (Norton and Poduslo, 1973). Brain homogenates (5%
w/v) were prepared in 0.32 M sucrose. An aliquot of the homogenate was
stored at80°C. The rest was layered over 0.85M sucrose and centrifuged
at 75,000 g for 30 min. Crude myelin was collected from the interface,
resuspended in water, and centrifuged at 75,000  g for 15 min. The
resultant pellet was osmotically shocked in deionized water to remove
contaminants from within myelin vesicles and centrifuged twice at
12,000  g for 15 min. The pellets were resuspended in 0.32 M sucrose,
layered over 0.85 M sucrose, and centrifuged at 75,000  g for 30 min.
Myelin was again collected from the interface, resuspended in deionized
water, and pelleted at 75,000 g for 15 min to remove residual sucrose.
Finally, myelin was resuspended in water and stored at 80°C. Equal
amounts ofmyelin preparationwere then processed for immunoblotting
using an anti-PrP antibody [ICSM-18 (White et al., 2003) or POM-1 (M.
Polymenidou andA. Aquzzi, unpublished observation)], an anti-NCAM
antibody (Research Diagnostics, Flanders, NJ), or an anti-GFAP anti-
body (Dako, Glostrup, Denmark).
Oligodendrocyte cultures.Mixed glial cell cultures containing oligoden-
drocytes and astrocytes were produced from 1-d-old neonatal mice as
described previously (McCarthy and de Vellis, 1980; Trotter and
Schachner, 1989). Cultures were prepared with high-glucose DMEM
supplementedwith 10% fetal bovine serum and replenished on day 4 and
every 3–4 d thereafter for 10 d with DMEM plus 10% heat-inactivated
horse serum. Oligodendrocytes were purified from mixed glial cultures
by differential detachment and negative selection of microglia by adher-
ence to hydrophobic plastic. Purified oligodendrocytes were then plated
onto glass or plastic culture chambers coated, respectively, with 100 or 10
g/ml poly-L-lysine. Oligodendrocyte precursors were expanded with
PDGF- and FGF-supplemented SATO medium [400 ng/ml T3,
400 ng/ml T4, 2 mmol/L glutamine, 50 U/ml penicillin, 50 g/ml strepto-
mycin, and 5ml of N2 supplement (Invitrogen, Paisley, UK)] for 2 d and
subsequently differentiated with 1% horse serum-supplemented SATO
medium. After 3 d of differentiation, cells were washed with PBS and
homogenized in PBS containing 0.5% NP-40, 0.5% sodium deoxy-
cholate, and protease inhibitors (Roche). Homogenate was then incu-
bated on ice for 30 min and centrifuged at 10,000 rpm for 15 min at 4°C.
Equal amounts of lysate were then processed for immunoblotting with a
mouse monoclonal antibody to PrP (ICSM-18) (White et al., 2003) and
with a mouse monoclonal anti-actin antibody (Chemicon).
Flotation assays. Flotation of detergent-insoluble complexes was per-
formed as described previously (Naslavsky et al., 1997). Appropriate
brain homogenates were extracted for 1 h on ice in cold lysis buffer (150
mM NaCl, 25 mM Tris-HCl, pH 7.5, 5 mM EDTA, and 1% Triton X-100;
total protein, 30 g in 100 l). Extracts were mixed with two volumes
(200 l) of 60% Optiprep (Axis Shield, Oslo, Norway) to reach a final
concentration of 40%. All lysates were loaded at the bottom of Beckman
Instruments (Fullerton, CA) ultracentrifuge tubes. A 5–30% Optiprep
step gradient in TNE (in mM: 150 NaCl, 25 Tris-HCL, pH 7.5, and 5
EDTA) was then overlaid onto the lysate (1300 l of 30% Optiprep and
300 l of 5% Optiprep). Tubes were centrifuged for 12 h at 4°C in a
TLS55 Beckman Instruments rotor at 100,000  g. Fractions (200 l)
were collected from the top of the tube and processed for immunoblot-
ting and visualization with an anti-PrP antibody [ICSM-18 (White et al.,
2003) or POM-1 (Polymenidou and Aquzzi, unpublished observation);
both detect the PrP core and display identical patterns] and an anti-
flotillin 1 antibody (BD Transduction Laboratories, Lexington, KY).
Western blot analysis of myelin proteins. Brains and spinal cords were
removed and homogenized in lysis buffer containing 1% Nonidet P-40,
0.5% sodium deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate
(Fluka, Basel, Switzerland), and protease inhibitors (Roche) in PBS. Ho-
mogenates were incubated on ice for 30 min and centrifuged at 10,000
rpm for 10 min at 4°C. Equal amounts of lysate (10 g of protein for
spinal cord and 20 g of protein for brain homogenate) were separated
by electrophoresis on 12% SDS-PAGE gels and transferred to nitrocellu-
lose membranes. The membranes were probed with antibodies to MBP
(Chemicon), myelin-associated glycoprotein (MAG) (Chemicon), pro-
teolipid protein (PLP) (Chemicon), 2,3-cyclic nucleotide 3-
phosphodiesterase (CNP) (Abcam, Cambridge, UK), and actin (Chemi-
con). The amount of MBP, MAG, and actin was quantified using a
VersaDoc model 4000 Imaging System (Bio-Rad, Zurich, Switzerland).
Northern blots. Brains were collected and immediately snap frozen in
liquid nitrogen before storage at 80°C until required. Total RNA was
isolated using Trizol (Invitrogen, Basel, Switzerland) with a T18 Basic
Disperser (Ika Works, Staufen, Germany). Northern blot hybridization
experiments were performed according to standard procedures (Sam-
brook and Russell, 2001) using 15 g of total RNA. Random primed
[- 32P]deoxyCTP probes were prepared from20 ng of gel-purifiedDNA
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homologous to target transcripts using a Rediprime II random priming
kit (Amersham Biosciences, Otelfingen, Switzerland) and purified with
Nick Sephadex G50 columns (AmershamBiosciences). Prehybridization
and hybridization were performed overnight at 42°C using Ultrahyb
(Ambion, Austin, TX), containing 1 106 cpm/ml radiolabeled probe,
100 g/ml denatured herring sperm DNA (Catalysis), and 20 g/ml
denatured yeast tRNA (Fluka). Posthybridization washes were per-
formed according to Ultrahyb instructions. Hybridization signals were
quantified using Fujifilm (Tokyo, Japan) imaging plate technology (BAS-
1800II) and normalized for variations in RNA loading by subsequent
probing with an excess of 18S ribosomal RNA cDNA probe (Miele et al.,
1998).
Results
Myelinopathy and axonal degeneration inPrPo mice
Hemizygous hg-PrP(32–134) tg/ transgenic mice, which ex-
press amino proximally truncated PrPC under transcriptional
control of a half-genomic Prnp minigene (Fischer et al., 1996)
(henceforth termedPrPmice) were bred to Prnpo/omice. The
resultingmice (termedPrPo), hemizygous for the hg-PrP(32–
134) transgene and devoid of both endogenous Prnp alleles, de-
veloped CGCdegeneration as described previously (Shmerling et
al., 1998) (Fig. 1a,b). In addition, histological analysis of termi-
nally sick PrPo brains revealed additional coarse vacuolar de-
generation of the intrapontine part of cranial nerves (Fig. 1d,e).
Also, substantial areas of white matter in the cerebellum, the
brainstem, as well as the anterior and lateral spinal cord columns
exhibited large vacuoles, astrogliosis, and activated microglia/
macrophages (Fig. 1m–r).
We also bred heterozygous and homozygous hg-PrP(32–
121) tg transgenic mice, which express a Prnp version with a
smaller deletion than the hg-PrP(32–134) transgene, to the
Prnpo/o genetic background. We found that both the hg-
PrP(32–121) and hg-PrP(32–134) transgenes induced analo-
gous white-matter lesions in Prnpo/o mice (data not shown).
Therefore, in all experiments described below, we used PrPo
mice as a general paradigm for the toxicity of amino proximally
truncated PrPC.
Myelinated fibers in spinal cord and cerebellar white matter
displayed severe axonal loss associated with large vacuoles and
degeneration of myelin sheaths into condensed spheroids (Fig.
2a–f). Semithin sections and electron microscopy did not evi-
dence any abnormality in myelin thickness, spacing, and period-
icity in PrPo and PrP mice (Fig. 2i), but many individual
sheaths displayed vacuoles, especially around large axons. Axonal
pathology was evident in the latter areas. Some axons were swol-
len and featured accumulation ofmitochondria and dense bodies
(Fig. 2j,k). Other axons suffered from compromised adhesion to
their myelin sheaths, evident as periaxonal splitting over broad
portions of the axolemma and detachment from themyelin wrap
(Fig. 2l,m). Many axons had completely degenerated, leaving be-
hind empty myelin rings or collapsed and condensed residual
myelin ghosts (Fig. 2n,o).
Axon–myelin pathology may result from developmental my-
elination failure or, alternatively, from degeneration of myelin-
ated axons after completion of normal development. This ques-
tion was addressed by studying semithin spinal cord and
cerebellar white-matter sections from postnatal day 25 mice,
Figure1. White-matter pathology inPrP o andPrnp o/ZHIImice.a–l, Vacuolar degeneration in the cerebellar peduncles (a– c), the intrapontine segments of the trigeminal nerve (d–f ), and the
anterior spinal cord columns (g–i) of 4-month-old PrP o and 18-month-old Prnp o/ZHII mice. Prnp o/ZHII mice showed additional vacuolation of forebrain white-matter tracts, including the
pyramidal tracts (l ) and the corpus callosum (data not shown).PrP transgenic mice hemizygously expressing wild-type Prnp (PrP) did not develop pathological changes (a, d, g, j). m–r,
Astrogliosis andmicroglia activation in thewhitematter ofPrP o but not ofPrPmice. Astrocyteswere visualizedwith antibodies toGFAP (m,n),whereas activatedmicroglia andmacrophages
were stained with antibodies to CD11b (o, p) and MHC-II (q, r).
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shortly after completion of themyelination process.We foundno
vacuolation, hypomyelination, or axonal loss at this early stage
(Fig. 2g,h), suggesting that pathological changes occur after my-
elination and are of degenerative rather than developmental
origin.
Although florid apoptosis was only found in CGCs, as de-
scribed previously (Shmerling et al., 1998), abnormal accumula-
tions of perikaryal phosphorylated neurofilament proteins were
visible in degenerating CGCs, as well as in brainstem and spinal
cord neurons (Fig. 3), implying that neurons other than CGCs
may also be affected by PrP toxicity. Additionally, this suggests
that axonal damage and pathologic cytoplasmic accumulation of
phosphorylated neurofilament are a primary consequence of
PrP expression rather than secondary to neuronal cell death.
We considered whether axon–myelin degeneration might result
from oligodendroglial damage. However, no apoptosis was
found in the white matter of diseased animals (Fig. 3), suggesting
that oligodendrocyte survival was not generally impaired by
PrP. Therefore, general oligodendroglial cytotoxicity is unlikely
to account for white-matter pathology.
White-matter pathology in Prnpo/omice overexpressing Dpl
The prion protein homolog Dpl bears structural resemblance to
PrP (Luhrs et al., 2003) and is encoded by the Prnd gene, which
is situated 16 kb 3 of Prnp. In homozygous PrnpZHII/ZHII and in
compound heterozygous PrnpZHII/o mice, loxP-mediated dele-
tion of the entire third Prnp exon induces atypical intergenic
splicing patterns that place Dpl under transcriptional control of
the Prnp promoter, thereby leading to Dpl overexpression in
brain (Weissmann and Aguzzi, 1999; Rossi et al., 2001). Overex-
pression of Prnd leads to cerebellar degeneration, possibly by
similar mechanisms as PrP (Moore et al., 1999; Genoud et al.,
2004). We therefore analyzed the white matter of 18-month-old
PrnpZHII/o mice with advanced clinical disease. We found white-
matter vacuolation similar to that of PrPo mice (Fig. 1c,f,i).
Unexpectedly, white-matter disease was not restricted to cerebel-
lum, brainstem, and spinal cord, but extended into the forebrain
whitematter, the pyramidal projections, and the corpus callosum
(Fig. 1j–l).
Oligodendroglial PrPC represses leukoencephalopathy but
not granule cell degeneration
Axons and their myelin sheaths are functionally dependent on
each other: degeneration in one compartment may result in sec-
ondary damage to the other compartment. Alternatively, damage
may result from parallel primary toxicity to both compartments.
If myelin-producing oligodendrocytes were a primary target of
mutant PrPC and Dpl, selective oligodendrocytic expression of
PrPC should repress white-matter pathology. We therefore
crossed PrPo mice to tg640 mice, which express full-length
PrPC under transcriptional control of amyelin basic protein pro-
moter fragment (Fig. 4a) (Prinz et al., 2004).
Hemizygous expression of the MBP-PrP transgene signifi-
cantly delayed the onset of tremor and ataxia (mean time of on-
set, 74  3 vs 43  2 d; p  0.0001) (Table 1, Fig. 4a,c) and
reduced the typical wasting of PrPo mice (body weight at 8
weeks of age, 22.2  0.39 vs 14.80.29 g; p  0.0001). PrPo
mice reached terminal disease at 3–4 months of age, with severe
wasting and hindlimb paralysis. In contrast, PrPoMBP-PrPtg/
littermates were ataxic, but weight loss was not as severe as in
Figure 2. Axon andmyelin degeneration inPrP o and Prnp o/ZHII mice.a–f, Toluidine blue-stained semithin sections of spinal cord (a– c) and cerebellar whitematter (d–f ) of clinically healthy
PrP (a,d) and terminally sickPrP o (b,e) andPrnp o/ZHII (c, f )mice. Axonal loss, vacuolation, andaxon–myelindegenerationwere visible inPrP o andPrnp o/ZHIImicebut absent fromPrP
mice. No axon–myelin degeneration was seen in 25-d-oldPrP o mice (g, h), suggesting that it is a late-onset pathology. Scale bar, 20m. Electron microscopic analysis showed regular spacing
and periodicity of PrP omyelin (i), whereasPrP o whitematter presentedwith axonal swellings and spheroids with accumulation of membranous organelles, mitochondria, and undefined dense
bodies (j, k), as well as defects in axon–glial adhesion (l, m) with axon–myelin detachment and optically empty myelin cavities (asterisk). n, o, More advanced stages of degeneration included
axonal degeneration with empty myelin rings (arrow) and collapse of myelin in condensed multilamellar spheroid structures (arrowheads). Scale bar, 5m.
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PrP° mice. The weight of 1-year-old PrPoMBP-PrPtg/ was
still 17–19 g. Remarkably, thesemice achieved long-term survival
(400 d), with stable or minimally progressing disease, whereas
the mean survival time of PrPo littermates was 99 5.3 d (Fig.
4a,c). Histological analysis showed repression, but not complete
rescue, of axon–myelin degeneration and white-matter vacuola-
tion (Fig. 4g–j). Instead, no rescue of CGC was observed (Fig.
4e,f), confirming that white-matter disease is unrelated to CGC
degeneration. These results strengthen the conjecture thatmyelin
is a direct target of PrP toxicity.
Compound heterozygous PrnpZHII/ZHI mice develop neuro-
logical symptoms at 13–21 months and survive 18–24 months
(Rossi et al., 2001). Also in these mice, intercross with tg640mice
delayed onset of disease, prolonged survival (Table 1, Fig. 4b,d),
and repressed axon–myelin degeneration (Fig. 4m–p), adding
support to the hypothesis that Dpl and PrP share the same
pathological basis. However, expression of the MBP-PrP trans-
gene did not rescue Purkinje cell degeneration (Fig. 4k,l).
Neuronal PrPC expression antagonizes CGC degeneration
but does not prevent leukoencephalopathy
Neuronal processesmay conceivably represent the primary target
of mutant PrP toxicity, whereas myelinopathy may be secondary
to axonal degeneration. If so, oligodendrocytes may provide
PrPC to the axon–myelin interface, which would abrogate any
cell-autonomous axonal PrP toxicity in trans. Intercellular
transfer of glycosylphosphatidylinositol (GPI)-anchored protein
(a phenomenon called “cell painting”) was described for CD4
(Anderson et al., 1996) and for PrPC in vitro (Liu et al., 2002).
Alternatively, PrPC may act as a ligand and trigger signaling
through receptors expressed by neighboring cells.
These scenarios were tested by crossingPrPomice withmice
Figure 3. Neuronal damage but no oligodendroglial or extracerebellar apoptosis. a–j, Immunostains for phosphorylated neurofilaments. Pathological neurofilament deposits (arrows) were
evident inPrP o CGC (b), as well as in spinal (d) and brainstem (f ) neurons but not in hippocampal and cortical neurons (h, j), suggestive of selective neuronal pathology and possible axonal
impairment. No hyperphosphorylated neurofilamentswere found inPrP o Prnp/omice (a, c, e, g, i). In the CGC layer (asterisks), manyMAP-2 granule cells were terminal deoxynucleotidyl
transferase-mediated biotinylated UTP nick end labeling (TUNEL) positive (green, k), but noMAP-2 apoptotic cells were found in spinal cord (l ), brainstem (m), cortex (n), or hippocampus (data
not shown). No TUNEL cells were found in the white matter, which instead contained CNPase (red) oligodendrocytes (o, p). TUNEL/CNPase CGCs served as internal controls. Asterisks
delineate CGC layer and white matter (red). Nuclei are 4,6-diamidino-2-phenylindole positive (DAPI, blue). GCL, Granule cell layer.
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expressingmurine PrPC under transcriptional control of theNSE
promoter (Fig. 5a). NSE-PrP were crossed to mice lacking Prnp,
thus yielding NSE-PrPtg/Prnpo/o mice that are hemizygous for
the NSE-PrP transgene and homozygous for the ZHI Prnp null
allele. The latter mice (henceforth termed NSE-PrPo) express
PrPC in neurons including CGC at higher levels than wild-type
mice and do not develop any spontaneous pathological pheno-
type (O. T. Giger, B. Navarro, and A. Aguzzi, unpublished data).
Instead, PrPoNSE-PrP mice developed tremor and ataxia only
at 9–18 months and survived500 d. This confirms that neuro-
nal PrPC expression prolongs survival of PrPo mice (Table 1,
Fig. 5b). However, histological analysis of clinically sick animals
revealed leukoencephalopathy of similar severity in PrPo and
PrPoNSE-PrP mice but not in age-matched PrP animals
(Fig. 5c–h). Leukoencephalopathy was found also in pyramidal
tracts, corpus callosum, and optic tracts (data not shown), sug-
gesting that neuronal protection, by prolonging survival, allowed
for more extensive development of myelin pathology.
These findings indicate that neuron-restricted expression,
even at supraphysiological levels, does not suffice to prevent
PrP-induced leukoencephalopathy and adds strength to the
contention thatPrPo leukoencephalopathy is a primary myelin
pathology. PrPoNSE-PrP mice suffered also from CGC degen-
eration, although to a lesser extent than PrPo mice. This sug-
Figure 4. Oligodendroglial PrP C delays disease onset and represses leukoencephalopathy inPrP and Prnp ZHII/o mice. Hindlimb spastic paralysis resulting in pathological posture ofPrP o (a,
4 month old) and Prnp o/ZHII (b, 20 month old) mice (arrowheads), which was suppressed in age-matched littermates expressing additional MBP-PrP C (a, b). Prominent hunchback (arrow)
frequently developed inPrP omice butwas never seen inPrP oMBP-PrP littermates. Gait impairment differences betweenMBP-PrP o/o andMBP-PrP/omicewere evidenced by inspection of
ink footprints (right side of a, b). c, d, Delayed ataxia and tremor onset ( p  0.0001) as well as enhanced survival ( p  0.0001) in PrP o and Prnp ZHII/o animals expressing MBP-PrP.
Oligodendrocyte-specific PrP C expression did not rescue degeneration of CGC in PrP o (e, f ) mice or of Purkinje cells in Prnp ZHII/o mice (k, l ). Subtotal CGC layer loss (arrows) was visible in
4-month-old PrP o mice regardless of MBP-PrP expression (e, f ). Similar densities of residual Purkinje cells (arrows) were detected in 18-month-old MBP-PrP/o (k) and MBP-PrP o/o (l )
littermates. In contrast, MBP-PrP efficiently repressedwhite-matter pathology (g–j,m–p). Intactmyelin and no vacuolationwere visible in the spinal whitematter of aPrP oMBP-PrPmouse (h),
whereas a terminally sickPrP o littermate (g) displayedadvanceddegenerationwithabundant vacuolationand subtotalmyelin loss. Toluidineblue-stained semithin sections showeddegenerated
myelin spheroids but no vacuolation and increased numbers of large-caliber axons in MBP-PrP mice (j) compared with MBP-PrP o/o mice (i). White-matter disease was also repressed in
Dpl-expressingPrnp ZHII/omice (m–p),withnoaxon–myelindegenerationdetectable in semithin sections (p). Note the increaseddensity ofmyelinated fibers entering theanterior hornof the spinal
cord in MBP-PrP/o mice (m, n, arrowheads). HE, Hematoxylin-eosin stain.
Table 1. Genetic, clinical, and histopathological features ofPrP- and Dpl-induced diseases
Name Genotype Age at disease onset (days) Survival (days) Neuronal degeneration White-matter disease
PrP Hg-PrP(32–134); Prnp/0 No disease (n	 11) 600 None None
PrPo Hg-PrP(32–134); Prnpo/o 43  2 (n	 11) 99  5.3 Full CGC degeneration at 3
months
Severe at 3 months
MBP-PrP Prnpo/o; MBP-PrPtg/ No disease (n	 11) 600 None None
NSE-PrP Prnpo/o; NSE-PrPtg/ No disease (n	 12) 600 None None
PrPoMBP-PrP Hg-PrP(32–134); Prnpo/o; MBP-PrPtg/ 74  2 (n	 12); p 0.0001*  400; p 0.0001 Full CGC degeneration at 3
months
Mild and stable
PrPoNSE-PrP Hg-PrP(32–134); Prnpo/o; NSE-PrPtg/ 418  30 (n	 10); p 0.0001 600; p 0.0001 Partial CGC degeneration at
8–20 months
Severe at 8–20 months
PrnpZHII/ Heterozygous PrnpZHII; overexpresses Dpl None (n	 7) 700 None None
PrnpZHII/ZHII ZHI/ZHII Prnp alleles; deficient in PrPC 540  30 (n	 14) 630  2.1 Purkinje cell degeneration Severe at 18–22 months
PrnpZHI/ZHII; MBP-PrP ZHI/ZHII; Prnpo/o;MBP-PrP/ 660  17.4 (n	 15); p 0.005 700; p 0.0001 Purkinje cell degeneration Mild and stable
Significance p values were derived by comparing mean survival or disease onset times of transgenic and control mice (unpaired Student’s t test).
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gests that neuron-restricted expression of PrPC is beneficial but
insufficient to completely prevent neuronal death (Fig. 5c,d) and
raises the possibility that CGC may suffer (at least in part) from
deafferentation after degeneration of white-matter fibers inner-
vating the granule cell layer.
PrPC is present in purified myelin of wild-type and
MBP-PrP mice
Myelin was isolated from brains of NSE-PrPo, MBP-PrPo,
Prnpo/o, PrPo, and Prnp/ (wild-type) mice (age, 2–3
months). Sizable amounts of PrPC were detected inmyelin prep-
arations of Prnp/, MBP-PrP, and PrPo mice (Fig. 6a). How-
ever, we found PrPC also in purified myelin of NSE-PrP mice,
whose oligodendrocytes do not express PrPC (Fig. 6a,d). Poor
fractionation with neuronal or astrocytic components contami-
nating the myelin preparations appears to be very unlikely, be-
cause GFAP and NCAM, which would be indicative of contami-
nation, were essentially removed (Fig. 6b,c). The 120 kDa isoform
of NCAM is the major isoform found in oligodendrocytes and
myelin sheaths (Bhat and Silberberg, 1988). Intriguingly, PrP
brain homogenates displayed prominent NCAM 180, as well as
two additional NCAM bands of unknown origin, which will be
characterized in future studies. The presence of PrPC inmyelin of
NSE-PrP mice, therefore, suggests that axolemmal PrP under-
goes high-affinity interactions with myelin membrane proteins,
as shown for other proteins of the myelin–axolemmal complex
(Menon et al., 2003). Alternatively, neuronally synthesized PrPC
may be transferred onto myelin sheaths by cell painting, which
was shown to be highly efficient in the case ofGPI-linked proteins
(Anderson et al., 1996).
Unglycosylated PrPC seems to be predominant in myelinic
PrPC (Fig. 6a), similarly to what was observed in MBP-PrP mice
(Prinz et al., 2004). The intense low-molecular-weight PrPC
bands inMBP-PrPmicemight reflect deg-
radation of unglycosylated PrPC, because
glycosylation is known to influence the
stability of proteins.
PrP and PrPC inMBP-PrPmice are
localized in lipid rafts
PrPC localizes to lipid rafts (Naslavsky et
al., 1997; Meier et al., 2003), in which it
may exert a physiological function by in-
teracting with signaling molecules. Dpl is
also found in rafts (Massimino et al.,
2004). If toxicity of PrP and Dpl results
from interference with some PrPC-
mediated signaling pathway and toxicity is
counteracted by PrPC, these three proteins
may compete for the same partners on
rafts. Moreover, PrP and Dpl may dis-
rupt normal axon–glia interaction and ad-
hesion, whose integrity depends on GPI-
anchored and transmembrane proteins
(Falk et al., 2002; Marcus et al., 2002; Bar-
tsch, 2003; Vinson et al., 2003). To inves-
tigate the topology ofPrP, we performed
flotation assays on Optiprep gradients
with cold Triton X-100-treated PrPo
brain extracts. PrP was detected in low-
density, detergent-insoluble fractions and
displayed buoyancy similar to that of PrP
and flotillin (Fig. 6f–j). These characteris-
tics strongly suggest that PrP is indeed localized in lipid rafts
and colocalized with wild-type PrPC. Therefore, cytotoxicity is
unlikely to be attributable to inappropriate membrane targeting
of PrP. In addition, PrPC from MBP-PrP mice associated with
rafts similarly to PrPC from wild-type mice (Fig. 6i). Unglycosy-
lated PrPC was the dominant moiety, similar to PrPC isolated
from myelin.
NeitherPrP nor Dpl affect myelin protein expression
Leukoencephalopathy inPrPo andPrnpZHII/omice had features
suggestive of compromised axon–glial adhesion similar to those
described inmice lackingMAGandmyelin galactolipids (Marcus
et al., 2002), as well as in mice deficient for PLP (Griffiths et al.,
1998). In addition, we found axonal swellings similar to those of
Cnp1/ mice (Lappe-Siefke et al., 2003). Moreover, in mice
deficient for these diversemyelin proteins, oligodendrocytes pro-
duce appropriately thick myelin sheaths. These findings raised
the question as to whetherPrP andDplmight affect the synthe-
sis or the stability of the abovemyelin components. Therefore, we
analyzed the myelin content in whole brain and spinal cord ho-
mogenates of Prnpo/o, Prnp/, PrPo, and PrnpZHII/o mice
(age, 2 months). MAG, MBP, PLP, and CNP transcription and
protein content were assayed with Northern and Western blots
(Fig. 7a,b). The amount of MAG and MBP protein was normal-
ized against actin (Fig. 7c). These analyses revealed that both the
transcription and the steady-state protein concentration of all
investigated myelin proteins were unchanged in PrPo and Prn-
pZHII/o mice.
Discussion
Overexpression of amino proximally truncated PrPC variants
collectively termedPrP, (Shmerling et al., 1998), or of the struc-
tural PrPC homolog Dpl (Weissmann and Aguzzi, 1999; Behrens
Figure 5. Neuronal PrP C delays disease onset and rescues survival but does not prevent axon–myelin degeneration. a, Sche-
matic drawing of the DNA construct used to generate NSE-PrP transgenic mice. b, Neuron-specific wild-type PrP C expression
delayed onset of ataxia and tremor inPrP omice for long periods ( p 0.0001) but did not entirely prevent disease. CGC rescue
in PrP oNSE-PrP transgenic mice (c) was less than in PrP mice (d), yet residual granule cells at 12 months of age were
indicative of decelerated CGC degeneration. Instead, spinal white matter underwent degeneration similarly toPrP o animals
with vacuolation and axonal loss (e,g), in contrast toPrPmice (f,h). Ink footprints over c andd (obtained as in Fig. 4) indicate
that ataxic gait ofPrP o mice was suppressed to a similar extent by the wild-type Prnp allele and the NSE-PrP transgene.
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et al., 2002), triggers neuronal degeneration. We now report that
both PrP and Dpl elicit additional leukoencephalopathy. These
pathologies were not entirely expected, because PrP-related dis-
eases are thought to affect primarily neurons (Chiesa et al., 1998,
2000; Hegde et al., 1998, 1999; Shmerling et al., 1998; Rossi et al.,
2001). Conversely, myelin sheath damage and neuroaxonal dys-
trophy (Liberski et al., 2002), as well as cytopathic changes in
oligodendrocytes (El Hachimi et al., 1998), have been noted in
human and animal TSEs.
Myelinopathy, rather than neuronal damage, may be a major
determinant of lethality in Shmerling’s syndrome, because
oligodendrocyte-restricted expression of PrPC selectively sup-
presses leukoencephalopathy and restores long-term survival. In-
stead, neuron-restricted expression of PrPC, even at supraphysi-
ological levels, does not prevent white-matter degeneration.
These data indicate that leukoencephalopathy is not just a conse-
quence of neurodegeneration but suggest a primary role of oligo-
dendrocytes in white-matter disease. Oligodendrocyte-restricted
PrPC may repress in trans the axonal pathology elicited by mu-
tant PrP. A cellular signal might be transduced through PrPC
from oligodendrocytes to axons, analogously to other GPI-
anchored proteins (such as F3 andNCAM120) that play a role in
axon–myelin interactions (Falk et al., 2002). Because PrPC binds
in vitro to the transmembrane and GPI-linked forms of NCAM
(Schmitt-Ulms et al., 2001), it might contribute to the very same
pathways. Alternatively, PrPC may instruct oligodendrocytes to
release factors necessary for axonal survival (Wilkins et al., 2003).
Direct toxicity of PrP and Dpl to oligodendrocytes seems to be
unlikely, because we did not observe oligodendrocytic cell death
or ultrastructural abnormalities in oligodendrocytes. Both
oligodendrocyte- and neuron-restricted expression delayed the
clinical course of Shmerling’s disease, yet only endogenous PrPC
expression, which occurs on both neurons and glia (Moser et al.,
1995), brought about complete rescue. Therefore, both neuronal
and oligodendrocyte PrPC expression are needed for mainte-
nance of the axon–myelin interface in PrP mice.
Surprisingly, neuron-specific PrPC expression, even at supra-
physiological levels, did not completely rescue CGC degeneration.
Perhaps ongoing degeneration of white-matter fibers innervating
the granule cell layer participates indirectly in granule cell degener-
ation, e.g., by deafferentation and neuronal “dying back.” The de-
layed onset of myelinopathy in PrPoNSE-PrP mice might be re-
lated to the presence of PrPC in NSE-PrP myelin which, in turn,
might be attributable toGPI cell painting or to high-affinity interac-
tion of axonal PrPC withmyelin components.
Leukoencephalopathy in PrPo and PrnpZHII/o mice had fea-
tures suggestive of compromised axon–glial adhesion, including
axonal swellings similar to those described in mice lacking MAG
and myelin galactolipids (Marcus et al., 2002), PLP (Griffiths et
al., 1998), andCnp1 (Lappe-Siefke et al., 2003). However, expres-
sion ofMAG,MBP, PLP, andCNPwas not affected inPrPo and
PrnpZHII/o mice, suggesting that disturbance of myelin and ax-
onal physiology is directlymediated byPrP andDpl rather than
by dysmetabolism of myelin proteins.
The overlapping patterns of (1) Dpl- and PrP-induced leu-
koencephalopathy, (2) their modulation by coexpression of full-
length PrPC (Moore et al., 1999; Li et al., 2000; Rossi et al., 2001),
(3) the structural homology between Dpl and PrP (Luhrs et al.,
2003), and (4) the abrogation of neurodegeneration by removal
of Dpl from PrnpZHII/ZHII mice (Genoud et al., 2004) all suggest
that PrP and Dpl trigger similar pathogenetic mechanisms.
What might be the common structural basis of such pathologies?
Of all aminoproximal deletions thatwere tested (Shmerling et al.,
1998), only those that disrupt the highly conserved hydrophobic
TM1 region (amino acids 113–134) provoked pathologies that
were prevented by wild-type PrPC.
Two possible molecular mechanism of toxicity have been put
forward. Shmerling et al. (1998) proposed that the amino proxi-
mal region of PrP represents an effector domain, whose deletion
Figure 6. PrP C andPrP are present in purifiedmyelin and detergent-insolublemembrane
fractions. PrP C expressionwas analyzedbyWestern blotting of brain homogenates,myelin prepara-
tions, and cultured oligodendrocyte lysates of various genotypes.a, Brain homogenate (10g) or 5
g ofmyelin were loaded in each lane. Myelin preparations were analyzed for impurities by neural
cell adhesionmolecule (anti-NCAM,b) and an astrocytic component (anti-GFAP, c). d, Equal protein
amountsofoligodendrocyte lysatesofwild-type,Prnp o/o, andNSE-PrPmicewere loaded.e,-Actin
was visualized as a loading control. Optiprep fractions of Triton X-100-treated cerebral homogenates
were analyzed for PrP C expression on immunoblots.PrPo (f ),PrPo;Prnp/o (g), Prnp/ (h),
andMBP-PrP o (i) tissueswere analyzed. j, Detectionof flotillin, a 48 kDamarker protein of lipid rafts.
TruncatedPrP Cwasprimarily localizedinthehigh-density,detergent-insolublefraction, indicatingits
presence inmembrane rafts.
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abolishes trophic signaling and partially reduces the affinity of
PrPC for its hypothetical ligands. According to this scenario, re-
moval of the amino proximal confers recessive-negative toxic
properties to PrP that are abolished if PrP is displaced by
PrPC. In wild-typemice, oligodendrocytic PrPCmight transduce
survival signals by interacting with axonal molecules. Leukoen-
cephalopathy may occur because PrP abrogates such trophic
signals. The absence of such phenotype in Prnp/mice suggests
the existence of a functional homolog provisionally termed 
(Shmerling et al., 1998).
Alternatively, PrPC and its homologs may form homo- and
hetero-oligomers. AlthoughPrP andDpl homo-oligomersmay
be toxic to neurons, participation of full-length PrPC to such
complexes would “dope” their stoichiometry, hence abolishing
their toxicity (Behrens and Aguzzi, 2002).
It will be interesting to test which of the above hypotheses, if any,
reflects themechanismofPrP/Dpl-associateddamage to theaxon–
myelin complex. The finding that full-length prion protein, specifi-
cally expressed in oligodendrocytes and found in myelin, represses
these defects suggests that PrPC plays a role in myelin physiology,
oligodendroglial-mediated axonal support, and axon–myelin inter-
actions. This contention is supported by the finding that aged
Prnp/mice suffer from peripheral demyelination. Both leukoen-
cephalopathy and CGC degeneration are suppressed by coexpres-
sionofPrPC, suggesting that themolecularpathogenesisof these two
diseases is similar.
In addition to its role in prion disease
pathogenesis, repression of PrP/Dpl-
associated neurodegenerative pathologies
is likely to represent the most thoroughly
characterized function of PrPC. As shown
by the present study, the neurodegenera-
tive syndromes induced by PrP provide
an accessible experimental system for
studying function of PrPC in vivo by re-
verse genetics.
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